Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

ures before complete patient access to Esbriet is achieved.
  • Mid-Sized Countries (MSC) – In addition to the seven MSC for which Esbriet pricing has been secured, the company anticipates launches in the remaining three MSC of Netherlands, Finland and Ireland by mid-2013, assuming that acceptable pricing and reimbursement conditions are negotiated in these countries.
  • Enrollment of InterMune's Phase 3 pirfenidone study, ASCEND, in the United States and certain additional territories was completed in January 2013.  ASCEND is a double-blind, placebo-controlled trial of 52 weeks duration with a primary endpoint of change in forced vital capacity (FVC) between baseline and Week 52.  The trial enrolled IPF patients with mild-to-moderate impairment in lung function and certain characteristics that the company believes enhance the probability of a successful study outcome.  Top-line results are expected in Q2 of 2014.
  • On January 22, 2013, InterMune completed a public offering of 15,525,000 shares of its common stock, including the underwriters' over-allotment, with net proceeds to the company of $145.7 million (after payment of underwriting discounts and commissions, and expenses).  InterMune also completed a concurrent public offering of $120.75 million aggregate principal amount of the company's 2.50% convertible Senior Notes due 2017, including the Note underwriters' over-allotment, with net proceeds to the company of $116.7 million (after payment of the underwriting discounts and commissions, and expenses).  The company has used proceeds from the convertible notes offering to repurchase and cancel $66.6 million of its outstanding $85.0 million aggregate principal amount 2015 Notes, and intends to repurchase the remaining $18.4 million of the outstanding 2015 Notes over time.
  • On February 14, 2013 InterMune announced that Sean P. Nolan has joined the company as Executive Vice President and Chief B
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... Sept. 17, 2014 Intarcia Therapeutics, Inc. ... from a study of the cost and predictability of ... th Annual Meeting of the European Association for ... today, Christian Frois , Ph.D., of Analysis Group, ... of planned Intarcia-sponsored, retrospective studies to characterize the prevalence ...
    (Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
    (Date:9/17/2014)... de septiembre de 2014  Cryoport, Inc. ... mundial de soluciones logísticas avanzadas criogénicas para ... vida, anunció hoy la contratación de Broekman ... sede en Rótterdam, Países Bajos, para proporcionar ... en rápido crecimiento. Según los términos del ...
    (Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
    Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
    ... Global Products, BASINGSTOKE, England, October 8 ... global specialty biopharmaceutical,company, announces that it has agreed ... Almirall for a cash consideration of $213m. The ... sodium),and VANIQA(R) (eflornithine hydrochloride), and six other non-promoted,products1 ...
    ... about the origins of quantum dot blinking, researchers ... Laboratory, the University of Chicago and the California ... characterize it on faster time scales than have ... also known as quantum dots, are being intensively ...
    ... to Vice President, Research Operations ... Non-Profit Foundation, CARLSBAD, Calif., Oct. 5 ... focused on the discovery and,development of small-molecule therapeutics ... diseases, today announced changes to its,research management. Dr. ...
    Cached Biology Technology:Shire Divests Non-Core Product Portfolio to Almirall 2Shire Divests Non-Core Product Portfolio to Almirall 3Argonne researcher studies what makes quantum dots blink 2Ardea Biosciences Announces Changes to Research Management 2Ardea Biosciences Announces Changes to Research Management 3
    (Date:9/15/2014)... from digestion to disease resistance. Despite the fact that ... the planet, more is known about belly-button bacteria than ... colleagues working on Panama,s Barro Colorado Island discovered that ... to more than 400 different kinds of bacteria. The ... 7,000 different kinds. , Bacteria in tropical forests may ...
    (Date:9/15/2014)... that lowland tapir populations may continue to drop in ... from the Office National de la Chasse et de ... Zoo Global reviewed data retrieved from camera traps in ... and compared this data to current harvest rates in ... tapirs in French Guiana," said Matthias Tobler, a scientist ...
    (Date:9/15/2014)... a morphine regimen can result in better pain control ... the dosage of the opioid needed to be effective, ... University. , The result could bring significant relief to ... felt in the arms and legs and associated with ... need for better treatments for neuropathic pain," said Fletcher ...
    Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
    ... University of Delaware have developed a "smart" hydrogel that can ... Over the past few decades, smart hydrogels have been created ... "The idea of a smart hydrogel that can release ... professor of materials science and engineering and biomedical engineering. "What,s ...
    ... Living organisms have adapted to the day-night cycle and, in ... are not completely known yet but its functioning has been ... of normal circadian rhythms can have deleterious effects on health; ... the time of feeding was shown to affect the ability ...
    ... of the white-throated sparrow has identified a biological pathway connecting ... wild to variation in their genome. The Proceedings ... is publishing the results of the experiments, conducted by the ... Psychology. The research, which comprised behavioral observations ...
    Cached Biology News:UD-developed smart gels deliver medicine on demand 2The internal clock and feeding rhythm set the pace of the liver 2Wild sparrow study traces social behaviors in the field to specific gene 2Wild sparrow study traces social behaviors in the field to specific gene 3Wild sparrow study traces social behaviors in the field to specific gene 4
    ... Anti-Natural Killer Cell Receptor-P1, ... Immunogen: Hybridoma produced ... from BALB/c mice immunized (BALB/c ... (LAK) cells and mouse myeloma ...
    ... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
    Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
    Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
    Biology Products: